UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1326) 1326
Patent (34) 34
Publication (14) 14
Magazine Article (5) 5
Book Chapter (3) 3
Conference Proceeding (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (574) 574
life sciences & biomedicine (561) 561
humans (501) 501
gastroenterology & hepatology (464) 464
gastroenterology and hepatology (313) 313
male (300) 300
female (292) 292
adult (277) 277
crohn's disease (201) 201
middle aged (199) 199
abridged index medicus (167) 167
ulcerative colitis (166) 166
inflammatory bowel disease (159) 159
crohn disease - drug therapy (113) 113
treatment outcome (113) 113
adolescent (101) 101
aged (99) 99
inflammatory bowel diseases (92) 92
risk factors (91) 91
young adult (84) 84
care and treatment (83) 83
infliximab (67) 67
life sciences (62) 62
severity of illness index (60) 60
analysis (57) 57
antibodies, monoclonal - therapeutic use (56) 56
gastrointestinal diseases (55) 55
remission induction (55) 55
clinical trials (54) 54
colitis, ulcerative - drug therapy (53) 53
crohn disease - diagnosis (52) 52
immunosuppressive agents - therapeutic use (52) 52
follow-up studies (51) 51
gastroenterology (49) 49
organic chemistry (49) 49
double-blind method (48) 48
retrospective studies (48) 48
time factors (48) 48
tumor necrosis factor-alpha - antagonists & inhibitors (47) 47
crohns disease (44) 44
gastrointestinal agents - therapeutic use (44) 44
intestine (44) 44
child (43) 43
patients (43) 43
pharmacology & pharmacy (43) 43
crohn disease - pathology (41) 41
animals (40) 40
endoscopy (40) 40
crohn disease - genetics (39) 39
incidence (39) 39
medical research (39) 39
quality of life (38) 38
ibd (37) 37
inflammatory bowel diseases - drug therapy (37) 37
medical colleges (37) 37
prospective studies (37) 37
anti-inflammatory agents - therapeutic use (36) 36
crohn disease - complications (36) 36
crohn’s disease (36) 36
inflammation (36) 36
intestinal mucosa - pathology (35) 35
crohn disease - immunology (34) 34
adalimumab (32) 32
aged, 80 and over (32) 32
colitis (32) 32
crohn disease - epidemiology (32) 32
medicine, experimental (32) 32
prognosis (32) 32
research (32) 32
chemistry (31) 31
health aspects (31) 31
metallurgy (31) 31
antibodies, monoclonal - adverse effects (30) 30
colitis, ulcerative - diagnosis (30) 30
crohn disease - surgery (30) 30
monoclonal antibodies (30) 30
antibodies, monoclonal, humanized - therapeutic use (29) 29
chemical sciences (29) 29
crohn disease - therapy (29) 29
general & internal medicine (29) 29
medicine, general & internal (29) 29
colonoscopy (28) 28
human necessities (28) 28
hygiene (28) 28
medical or veterinary science (28) 28
mice (28) 28
preparations for medical, dental, or toilet purposes (28) 28
[chim.orga]chemical sciences/organic chemistry (27) 27
case-control studies (27) 27
drug therapy, combination (27) 27
immunology (27) 27
immunosuppressive agents - adverse effects (27) 27
recurrence (27) 27
tumors (27) 27
medicin och hälsovetenskap (26) 26
surgery (26) 26
[sdv]life sciences [q-bio] (25) 25
azathioprine - therapeutic use (25) 25
colitis, ulcerative - pathology (25) 25
crohn disease - microbiology (25) 25
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1326) 1326
French (76) 76
German (7) 7
Portuguese (2) 2
Danish (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gut, ISSN 0017-5749, 05/2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus | 1506 | Inflammatory Bowel Disease
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article